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Abstract
Multinodular and vacuolating neuronal tumor (MVNT) is a new pattern of neuronal tumour
included in the recently revised WHO 2016 classiﬁcation of tumors of the CNS. There are 15
reports in the literature to date. They are typically associated with late onset epilepsy and a
neoplastic vs. malformative biology has been questioned. We present a series of ten cases
and compare their pathological and genetic features to better characterized epilepsy-
associated malformations including focal cortical dysplasia type II (FCDII) and low-grade
epilepsy-associated tumors (LEAT). Clinical and neuroradiology data were reviewed and a
broad immunohistochemistry panel was applied to explore neuronal and glial differentiation,
interneuronal populations, mTOR pathway activation and neurodegenerative changes. Next
generation sequencing was performed for targeted multi-gene analysis to identify mutations
common to epilepsy lesions including FCDII and LEAT. All of the surgical cases in this
series presented with seizures, and were located in the temporal lobe. There was a lack of any
progressive changes on serial pre-operative MRI and a mean age at surgery of 45 years. The
vacuolated cells of the lesion expressed mature neuronal markers (neuroﬁlament/SMI32,
MAP2, synaptophysin). Prominent labelling of the lesional cells for developmentally
regulated proteins (OTX1, TBR1, SOX2, MAP1b, CD34, GFAPd) and oligodendroglial
lineage markers (OLIG2, SMI94) was observed. No mutations were detected in the mTOR
pathway genes, BRAF, FGFR1 or MYB. Clinical, pathological and genetic data could
indicate that MVNT aligns more with a malformative lesion than a true neoplasm with origin
from a progenitor neuro-glial cell type showing aberrant maturation.
INTRODUCTION
Indolent cortical lesions provoking focal refractory epilepsy often
bridge a gap between focal developmental anomalies and low grade
tumors. A long history of seizures and a lack of progressive neurol-
ogy or MRI changes are characteristic of WHO grade I tumors,
such as ganglioglioma and dysembryoplastic neuroepithelial
tumors (DNT) (57). However, many hamartomatous or develop-
mental ‘overgrowth’ lesions, particularly the mTORopathies (13)
or those associated with mutations in the PI3K–AKT signaling
pathway (21), are characterized by abnormal cortical architecture
with excessive cell size and tumor-like mass effect, such as tuber-
ous sclerosis.
In 2007, we reported a unique case of a ‘diffuse gangliocytoma’
involving the temporal lobe in a patient with late onset epilepsy
which posed such a diagnostic conundrum (45). Pathology exami-
nation of an MRI visible lesion disclosed diffuse involvement of
the white matter by nodules of vacuolated ganglion cells; malfor-
mations as focal cortical dysplasia (FCD), mild malformation of
cortical development, nodular heterotopia were diagnoses consid-
ered in addition to a neuronal tumour. Recently reports of
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histologically similar lesions have been termed ‘Multinodular and
vacuolating neuronal tumors (MVNT)’ (7, 17, 24) and this entity is
now included in the current 2016 WHO classiﬁcation of CNS
tumors as a pattern of gangliocytoma but with ‘uncertain class
assignment’ (33). Indeed, it has been commented that these lesions
‘may even be malformative in nature’ and it is acknowledged that
further characterization is needed to fully understand their nosologi-
cal place among CNS neoplasms (34).
In this study, we review the clinical and pathological ﬁndings in
a series of ten cases of MVNT (including the case in our initial
report (45)). We explore the cellular differentiation and maturation,
genetic abnormalities, and potential epileptogenic mechanisms in
an aim to better explore its delineation between cortical malforma-
tion or an epilepsy-associated tumour in the context of long-term
focal epilepsy.
METHODS
Case selection
Seven cases of MVNT were ascertained from pathology review of
all glio-neuronal tumors and malformations in the Department of
Neuropathology and Epilepsy Society Brain and Tissue Bank at
UCL. A further three cases of MVNT were included from the Aca-
demic Medical Centre (Amsterdam, the Netherlands), Great
Ormond Street Hospital for children, (London, UK) and Hospital
Pedro Hispano, (Matosinhos, Portugal). There is ethical approval
for this study and all surgical patients consented for use of tissue,
clinical and MRI data in research. We also included fetal develop-
mental controls (from MRC-Wellcome Trust Human Developmen-
tal Biology Resource HDBR, UCL), conventional gangliogliomas/
low grade glioneuronal tumour (WHO grade I), temporal lobe cor-
tex adjacent to hippocampal sclerosis with mild malformation of
cortical development type II (increased white matter neurones (6,
32)), and FCD type II cases from epilepsy surgical patients, as
comparative control groups for immunohistochemistry (Supporting
Information Table S1 for details) or genetics studies.
Immunohistochemistry
Routine H&E and LFB/CV were performed on sections of all cases
using the Leica ST5020 Autostainer (Leica, Milton Keynes, UK).
From all cases we then selected a representative block and a panel
of immunohistochemistry markers (Table 1) was applied on 5 mm
formalin-ﬁxed, parafﬁn-embedded brain sections to explore: neuro-
nal differentiation (NeuN, neuroﬁlaments, synaptophysin, MAP2),
astroglial differentiation (GFAP and GFAPd), oligodendroglial lin-
eage and myelination (Olig2, SMI94/myelin basic protein (MBP))
and common glioma mutations (IDH1, ATRX and BRAF V600E).
In seven cases with sufﬁcient material available, a more extensive
immunohistochemistry panel was applied including cortical layer
speciﬁc markers (TBR1, TBR2, OTX1, N200, MAP1B), develop-
mental/stem cell markers (CD34, Reelin, PAX6, SOX2, Nestin,
DCX, PDGFRb), interneuronal subsets (calbindin, calretinin, par-
valbumin, NPY), chloride co-transporters (NKCC1, NKCC2), neu-
rodegenerative markers (p62, AT8, APP, mitochondria) and mTOR
pathway activation (pS6, Ser 240/244 and pS6, Ser 235/236).
Either automated immunohistochemistry was performed (Bond
Max Automated Immunostainer (Leica, Milton Keynes, UK)) or it
was carried out manually using standard protocols as previously
detailed (20) (Table 1).
Next generation sequencing
Next generation sequencing (NGS) of MVNT was carried out in
eight of the nine surgical samples (Case 7 not sequenced due to
lack of availability of frozen tissue and the post mortem Case 4
failed sequencing due to low quality of DNA). Tumour tissue was
manually micro dissected from 10 lm tissue sections. DNA was
extracted using the BiOstic FFPE Tissue DNA Isolation kit (MO
BIO, Carlsbad, CA, USA) according to the manufacturer’s instruc-
tions. NGS was performed using a customized Ion AmpliSeq
TM
Neurology Panel (ThermoFisher Scientiﬁc, Waltham, MA, USA)
for targeted multi-gene ampliﬁcation. This panel consists of the fol-
lowing genes; AKT1, AKT3, ATRX, BRAF, CDK6, CIC,
CTNNB1, DDX3X, DEPDC5, EZH2, FGFR1, FUBP1, H3F3A,
HIST1H3b, HIST1H3c, IDH1, IDH2, KDM6A, mTOR, MYB,
MYBL1, NPRL2, NPRL3, PIK3CA, PIK3R1, PIK3R2, PTCH1,
PTEN, SMARCA4, SMARCB1, SMO, SUFU, TP53. Libraries
were prepared using the Ion AmpliSeq Library Kit 2.0. The Ion
PGM Hi-Q Kit and Ion Chef Instrument were used for emulsion
PCR and template preparation. The Ion PGM Hi-Q sequencing Kit
with the Ion 318 V2 Chip and Personal Genome Machine were
used as sequencing platforms. DNA input was up to 20 ng, which
was measured by the Qubit 3.0 Fluorometer. Up to 20 specimens
were barcoded using the IonXpress Barcode Adapters for each Ion
318 V2 Chip. A mean coverage of 15003 per amplicon was estab-
lished, and the data were analyzed using JSI SeqNext (JSI Medisys,
Ettenheim, Germany). Of note, the selected sequencing panel was
developed to identify most mutations in the genes studied. How-
ever, not all exons of each gene were analyzed, thus there is a risk
of undetected mutations in tumour suppressor genes. Gene duplica-
tions were not detected, and the sequence analysis of MVNT was
compared to 22 samples with FCD type II and 8 glioneuronal
tumors.
Clinical data and MRI
The clinical notes from each case were reviewed for presenting
neurological symptoms and updated post-operative information.
MRI had been carried out in different centers using different MRI
sequences and protocols. All available pre-operative MRI scans of
surgical cases (Cases 1, 2, 5, 6, 8 and reports in the remainder)
were reviewed by a neuroradiologist (HRJ) in addition to post-
operative MRI ﬁndings of any disease progression/recurrence.
RESULTS
Of the 10 cases with MVNT, nine were surgical resections carried
out for treatment of epilepsy, and a further case was identiﬁed at
post-mortem as an incidental ﬁnding (Table 2). One surgical case
was previously reported as an unusual gangliocytoma (Case 1)
(45), and two further surgical cases were initially diagnosed as a
gangliocytoma and a demyelinating condition (Cases 2 and 3) fol-
lowing histopathological assessment; the PM case was diagnosed
as subcortical grey matter heterotopia (Case 4). The remaining six
surgical cases (all reported since 2014) were recognized as MVNT.
MNVT: Dysplasia or Neoplasia Thom et al
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Clinical features
Six of the ten cases were females. The mean age at seizure onset
was 29.7 years based on information available (Table 2) with a
mean age at surgery of 45 years (range 6–67 years). The single
post-mortem case was a 62-year-old male without a clinical diag-
nosis of epilepsy. In ﬁve surgical cases, the lesions primarily
involved the temporal lobe, and mesial structures (hippocampus,
amygdala or parahippocampal gyrus); the post-mortem lesion
involved the occipital lobe. Clinical outcomes were available up
to 14 years post-operatively, however four cases were recently
operated with less than 2 years of follow-up. Only one patient did
not become seizure-free post-operatively, and no case has docu-
mented lesion progression on MRI, even in cases with partial
resections (Table 2).
Neuroimaging features
Salient MRI features common to all cases included poorly deﬁned
regions of signal abnormality in the temporal lobe, typically
hypo-intense on T1 with hyperintensity on T2 and FLAIR
sequences, involving the cortex and straddling the subcortical
region with more clear involvement of the adjacent white matter
in some cases (Figure 1). A vague, corrugated contour was appa-
rent in some but without clear nodularity or cystic change.
Although the extent of the abnormality varied between cases,
there was no or minimal mass effect associated with these lesions.
There was no enhancement or restricted diffusion where investi-
gated. Clear involvement of the hippocampus was apparent in
Cases 1, 2, 8 and 9 (Figure 1A,B). There were no progressive
changes on serial images in the pre-operative period, in one case
with six interval MRI studies (Case 5, Figure 1C,D) and over
review periods of up to 8 years (Case 1, Figure 1A). Low grade
glioma was considered the likely diagnosis or, less likely cortical
dysplasia, based on imaging features. None of the lesions showed
progressive changes during the post-operative period (Table 2).
Neuropathology findings
Macroscopic abnormalities noted in ﬁxed, resected lobectomy
specimens included focal translucency or cavitation of the sub-
cortical white matter in the gyral cores of the temporal lobe white
matter (Figure 2A) or with plaque-like nodules or islands of grey
discoloration (Figure 2E). In the post-mortem specimen, nodules
of grey matter were noted in the subcortical white matter of the
right occipital lobe only.
Histological examination at low magniﬁcation in larger resec-
tions conﬁrmed islands or nodules, predominantly located in the
subcortical white matter or ‘sitting’ in the deeper cortical layers.
Coalescing or abutting nodular islands (Figure 2I) as well as areas
of more diffuse subcortical white matter involvement (Figure 2C)
were observed. The architecture and extent of the white matter
component at low power was best appreciated by reduced myelin
on myelin stained sections (LFB/CV or SMI94/MPB) (Figure 2B–
D,I) and for the cortical component, reduced synaptophysin (Fig-
ure 2F). In regions bearing cortical nodules, the laminar cyto-
architecture and myelo-architecture of the cortex was otherwise
undisturbed. The nodules were composed of large cells with over-
all gangliocytic morphology, prominent nucleoli with frequent
cytoplasmic vacuolation or peri-cellular vacuolation (Figure 2J).Ta
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Cells with more eosinophilic cytoplasm and rarer bi-nucleate cells
were present (Figure 2K). There was minimal clustering and no ori-
entation of vacuolated cells (VC) within nodules but arrangements
alongside vessels were noted in one case (Figure 2L). In addition to
the predominant VC, smaller oligo-like glial cells were intermingled,
but without satellitosis. The impression in some nodules was of
diminished cellularity compared to adjacent white matter (Figure
2M) although in other cases (Case 7) regions of diffuse hypercellu-
larity were noted. Mitotic activity and signiﬁcant pleomorphism was
lacking. Rosenthal ﬁbers or calciﬁcation were not present and promi-
nent perivascular inﬁltrates were noted in four cases.
In ﬁve cases, the involvement of the hippocampus was present,
with islands of VC in the white matter underlying the subiculum
(Figure 2D), CA1 and as well as parahippocampal gyrus white mat-
ter and amygdala. In Case 8, the mesial temporal component
showed cytology more typical for ganglioglioma with dysmorphic
ganglion cells, eosinophilic granular bodies (EGBs) (Figure 2N)
and nodules of spindled astroglial cells, even though the temporal
lobe component had the typical appearances of MVNT (Figure
2H); this suggested a tumour with hybrid features. Hippocampal
sclerosis was also noted in three cases.
Neuronal differentiation
Immunolabelling using the mature neuronal marker, NeuN, was
weak or negative (Figure 3A) in VC, in keeping with previous
reports (7, 24) but we conﬁrmed consistent, strong expression for
non-phosphorylated neuroﬁlament (SMI32) in VC in all cases (Fig-
ure 3B). Other neuroﬁlament antibodies (Table 1), including phos-
phorylated neuroﬁlament (SMI31), neuroﬁlament cocktail and
N200 labelled only occasional axons traversing through nodules
but VC were mainly negative. MAP2 highlighted VC and dendrites
(Figure 2H and 3C) and a proportion of the small multipolar cells
in nodules. In Cases 3 and 4, the MAP2 labelling was weaker in
VC compared to other overlying cortical neurones. Despite an
overall reduction of synaptophysin expression in the nodules (Fig-
ure 3E), imparting a ‘moth-eaten’ appearance to the cortical-white
matter border at low magniﬁcation (Figure 2F); a proportion of VC
showed weak cytoplasmic labelling in all cases (Figure 3D). In
Case 8 with a focal ganglioglioma component, stronger synapto-
physin labelling of atypical ganglion cells was noted compared to
the VC.
Cortical layer differentiation markers
Application of cortical layer and neuronal linage markers revealed
variable labelling of VC for TBR1; a proportion of VC in four of
eight MNVN showed strong nuclear positivity (Figure 3F) while in
other cases, VC were weak or negative. The overlying cortex
showed TBR1 nuclear labelling of neuronal cells in all cortical
layers. In Case 8 with the ganglioglioma component, dysplastic
neurons were negative with TBR1. There was no labelling of VC
for TBR2 in any case. Intense cytoplasmic labelling of VC for
OTX1 was noted in all cases apart from the post-mortem case (Fig-
ure 3G); in comparison the overlying cortex and normal white mat-
ter was negative with this marker in keeping with previous reports
(20). OTX1, therefore, appeared a speciﬁc marker to distinguish
VC from normal interstitial neurones in the white matter as well as
delineating the extent of the MVNT. With MAP1b, we also
observed intense cytoplasmic labelling of the VC and their dendri-
tic like processes in all cases (Figure 3H) in addition to labelling of
pyramidal cells of normal morphology in layers II, III and V of the
overlying cortex.
Glial lineage markers
GFAP accentuated variable proportions of small, multipolar astro-
glial cells and processes in the lesion typically merging with a
denser gliosis in the surrounding white matter (Figure 3I, bottom
inset). In Case 8 with a ganglioglioma component, a more promi-
nent GFAP-positive glial tumour component was conﬁrmed.
Figure 1. Neuroimaging features of multinodular and vacuolating
neuronal tumour. A. Case 1 (as reported in the original case
report(45)) showing marked signal change in the left temporal lobe,
parahippocampal gyrus and hippocampus on coronal FLAIR but with
minimal mass effect; little change was noted over 8 years. B. Case 8.
Abnormality was observed in the right mesial temporal region with
hyperintensity on coronal FLAIR sequence. C. Case 5. Initial FLAIR
MRI sequences at presentation highlighted a lesion in the right
posterior temporal lobe as a diffuse cortical abnormality, which did
not show significant growth on MRI, as shown in (D) at 21 months
following the initial scan. E. Case 6 shown with T2 and (F) FLAIR
sequences, highlighting a hyperintense abnormality and the cortical,
white matter interface in the left temporal lobe.
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GFAPd showed restricted expression in MVNT, localizing to the
nodules and diffuse components at low magniﬁcation (Figure 3I),
labelling small multipolar glial cells in proximity to VC and some-
times enveloping them (Figure 3I, top inset). In keeping with previ-
ous reports (7, 24) VC showed strong nuclear labelling for OLIG2
(Figure 3J); a proportion of the smaller glial cells associated with
the lesion were OLIG2-positive. NG2 and PDGFRa immuno-
markers did not show any consistent labelling of the surgical cases
or post-mortem tissue. However PDGFRb, which labels both peri-
cytes and NG2/oligodendroglial progenitor cells (18, 55), small
multipolar cells within in the nodules away from vessels as well as
in adjacent tissue were noted (Figure 3K); the large VC were nega-
tive with PDGFRb. MBP (SMI94) showed striking abnormalities,
correlating with overall reduction of myelinated ﬁbers in the lesion
as described above (Figure 2C,I). In addition, cytoplasmic membra-
nous or granular labelling of VC was noted for MBP (Figure 3L)
and the rims of empty vacuoles also highlighted.
Neurodevelopmental and interneuronal markers
VC were largely negative for reelin, and cells with the morphology
of Cajal–Retzius cells were not seen within the nodules, although
they were present in the overlying cortex. VC were also mainly
negative with PAX6 which showed nuclear labelling of a propor-
tion small cells in the vicinity of the nodules (Figure 4A). Consist-
ent cytoplasmic or membranous labelling of VC in MVNT with
SOX2 was seen in all cases studied, demarcating the nodular and
serpiginous islands of the lesion at low magniﬁcation (Figure 4B).
CD34-positive multipolar cells were present in all cases, ranging
from very occasional cells (Case 2) to extensive labelling (in Cases
7, 8) (Figure 4C). With DCX and nestin, only occasional VC were
positive (Figure 4D,E), both markers showed more prominent
labelling of small cells associated within the lesion. Nestin also
highlighted a population of bipolar cells with long processes in
some nodules (Figure 4E; inset). Calbindin, calretinin, parvalbumin
and NPY (Figure 4F) showed a normal morphology and distribu-
tion of interneurons in adjacent cortex and white matter. VC were
generally negative with these markers, apart from one case (Case 3)
which showed PV expression in VC (Figure 4G). Interneurons of
normal morphology and axonal networks were also intermingled in
the MVNT, although there was an impression for reduced numbers
compared to adjacent tissue in some cases (Figure 2G and 4F).
KCC1 showed strong cytoplasmic labelling of VC (Figure 4H) but
labelling with KCC2 was less distinct.
Neurodegenerative, mTOR pathway and cell
cycle markers
In none of the surgical cases were tangles noted in VC, and AT8 for
phosphorylated-tau was virtually negative. In the post-mortem case
with a neuropathology diagnosis of AD, the cortical nodules of the
MVNT, in fact, were strikingly spared from tau accumulation com-
pared to the adjacent cortex (Figure 4I) suggesting late acquisition of
degenerative changes. VC showed cytoplasmic labelling with APP
and intense labelling for p62 (Figure 4J) and anti-mitochondrial anti-
bodies (Figure 4K) compared to adjacent cortical and white matter
neurones. With mTOR pathway antibodies, anti-pS6 (ser235/236
and ser240/244), minimal labelling of VC was observed across all
cases; occasional dot-like positivity in the cytoplasm was noted in
some VC, in contrast to the intense labelling of scattered pyramidal
cells in the overlying cortex (Figure 4L; insets) and the dysmorphic
neurons of the ganglioglioma component of Case 8. However,
strong cytoplasmic labelling for pS6 antibodies of small glial-like
cells associated with the lesional nodules was noted (Figure 4L). A
high proportion of VC showed nuclear labelling with MCM2 (Fig-
ure 4M) in contrast to Ki67 labelling which was virtually absent in
VC, but noted mainly in small cells and inﬂammatory cells (overall
<5%). In all MVNT cases, immunohistochemistry for mutant
IDH1, ATRX and BRAF V600E mutations were negative.
Comparison of MVNT to controls groups
In ganglioglioma controls, Tbr1 nuclear labelling of dysmorphic
neurons was noted in one case (Supporting Information Figure 1A);
a variable proportion also showed cytoplasmic OTX1 positive label-
ling (Supporting Information Figure 1B) but more consistent label-
ling was observed with SOX2 (Supporting Information Figure 1C).
Figure 2. Macroscopic and low power histological features of
multinodular and vacuolating neuronal tumours (MVNT). A. Macroscopic
features of the temporal lobe specimen from Case 1 show areas of
breakdown/cavitation in the gyral cores and focal translucency of the
white matter. B. Luxol fast blue/cresyl violet stained section from Case 1
confirms lack of myelin in some gyral cores (arrow) and pale
hypomyelinated nodules at the cortical white matter junction extending
into the white matter (arrowhead). C. SMI94/myelin basic protein
confirms diffuse regions of poor myelination (arrow) and nodular like
patterns (arrowhead) in the white matter in Case 1. D. Abnormal nodular
islands of cells in the subiculum in Case 1, present on both sides of the
pyramidal cell layer, although predominantly in the subcortical region
(arrowhead). E. Macroscopic appearance of fixed 5 mm sections of the
temporal lobe in Case 2 shows islands of grey tissue in the white matter
of the inferior medial part of the specimen with an overlying normal-
appearing cortex. F. Synaptophysin labelling in Case 4 highlights the nod-
ules encroaching on the deep cortical layers with reduced labelling com-
pared to the adjacent cortex. G. Neuropeptide Y in Case 4 at low power
shows reduction of labelling within the cortical nodules compared to
adjacent cortex (arrowheads). H. MAP2 staining in Case 8 in the temporal
cortex shows variable patterns with reduced MAP2 labelling in some nod-
ules (arrowhead) compared to others (arrows). I. Myelin basic protein
staining (SMI94) in Case 4 highlights abutting, myelin-poor nodules. J. The
abnormal white matter regions are populated by single scattered cells
with a neuronal/ganglion cell appearance and prominent vacuolation of the
cytoplasm or vacuoles surrounding the cells. K. Occasional binucleated
cells were seen (arrowhead) and cells with more eosinophilic cytoplasm
were observed in MVNT after H&E staining. L. In some cases alignment
of the atypical cells along vessels was noted in the nodules (Case 4). M.
The border (arrowhead) between a nodule in MVNT(top half of figure) and
the white matter (lower half of figure) on cresyl violet stain gives the
impression of overall reduced cellularity, particularly for small
oligodendroglial-like cells in the nodules, compared to the adjacent white
matter. N. In Case 8, a focal area in the mesial temporal lobe showed
more typical appearances of a ganglioglioma, with dysplastic neurones
and eosinophilic granular bodies. Bar51cm for macroscopic images in A
and E;53mm for B–D, F–H; 50.5mm for I;5 100 microns for J, L–N and
550 microns for K (approximate based on original magnifications).
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Little evidence of nuclear labelling of gangliogliomas for OLIG2
was seen (Supporting Information Figure 1D) but strong labelling
with calbindin as previously noted (Supporting Information Figure
1E) (62) and also with p62 as previously reported (43). Dysmorphic
cells in ganglioglioma infrequently labelled with MCM2 in contrast
to MVNT (Supporting Information Figure 1F). In temporal lobe
white matter with mild MCD type II, strong Tbr1 labelling of inter-
stitial white matter neurons was noted (Supporting Information Fig-
ure 1G) but not OTX1 (Supporting Information Figure 1H), and
rare positive neurones were observed with SOX2 (Supporting Infor-
mation Figure 1I) or Mapb1b; OLIG2 was restricted to mature-
appearing oligodendroglia (Supporting Information Figure 1J). pS6
expression in TLE white matter showed occasional labelling of
white matter neurons and small glial cells (Supporting Information
Figure 1K) but no labelling with KCC1 (Supporting Information
Figure 1L). In fetal developmental controls, strong labelling, primar-
ily in the periventricular germinal matrix, was conﬁrmed with Tbr2,
OTX1 and SOX2 (Supporting Information Figure 1M–O).
Molecular genetics
Of the 33 genes studied, single mutations in SUFU was identiﬁed
in Case 2, and in EZH2 in Case 8 (Table 3). No mutations in
MTOR, DEPDC5, FGFR1, MYB or BRAF were identiﬁed in any
MVNT. Recurring synonymous SNPs in DEPDC5, SMO and
TP53 were present in all surgical MVNT tested, with less frequent
synonymous SNPs occurring in some MVNT only (Table 3 and
Supporting Information Table S2). We compared the MVNT to
FCD type II (22 samples) and 8 glioneuronal tumors; SUFU muta-
tion was present in one FCD type II case but not in other glioneuro-
nal tumors. Identical DEPDC5 and SMO E3 SNP also occurred in
all FCD type II samples and the majority of glioneuronal tumors,
while the other common SNPs did not occur in all FCD or glio-
neuronal tumors. Of note, a NPRL3 variant was found in 5/8
MVNT and 90% of FCD but none of the glioneuronal tumors. The
genetic and immunohistochemistry ﬁndings in MVNT are summar-
ized and compared to ﬁndings in controls as well as published data
on related tumors and malformations associated with long-term epi-
lepsy in Supporting Information Table S3.
DISCUSSION
In 2014, Huse et al., described ten cases of a novel low-grade neuro-
nal lesion, mainly associated with epilepsy and coined the term ‘mul-
tinodular and vacuolating neuronal tumour’ (24). Subsequently, ﬁve
more cases have been reported (7, 17, 39, 68), and this new entity
was added to the list of patterns of CNS neoplasms in the recently
revised 2016 WHO classiﬁcation (34). We present the pathology in
a further ten cases, including a case previously reported in 2007 as
an unusual vacuolated diffuse gangliocytoma (45). Our ﬁndings con-
ﬁrm their indolent behavior, and predominant involvement of the
temporal lobe presenting with late onset of epilepsy, typically in
adulthood. We have extended investigations into their neoplastic vs.
malformative nature, cell lineage and potential mechanisms of epi-
leptogenesis through the application of immunohistochemistry and
NGS. It remains possible that MVNT align more with developmental
anomalies than true neoplasms. Although these lesions are rare, it is
probable they have been previously unrecognized, being misdiag-
nosed as demyelinating conditions (7) or other more common lesions
encountered in epilepsy series (as listed in Supporting Information
Table S3) with which they share histological similarities.
Neoplasia or malformation
MVNT has been grouped as a pattern of gangliocytoma in the
revised 2016 WHO classiﬁcation of CNS tumors. Features in com-
mon with other low-grade epilepsy-associated tumors (LEATs)
(57) include a predilection for the temporal lobe, MRI characteris-
tics (39, 68), frequent CD34-positivity, and a mixed neuronal and
glial composition. We include the ﬁrst report of a case with mixed
features of both MVNT and conventional ganglioglioma in support
of a potential common origin, and we identiﬁed two cases with
novel mutations in SUFU and EZH2, although these mutations are
of uncertain signiﬁcance.
As previously noted (24, 45), some features of MVNT align
more with a malformation of cortical development or dysplasia
than a neoplasm, supported by evidence in this current study. This
includes (i) the lack of any growth on serial MRI or reported
regrowth, even following incomplete resection, (ii) no overt
increase in cellularity or conspicuous mitotic activity, (iii) lack of
expansive or inﬁltrative growth patterns with nodules ‘sitting’ in an
undisturbed laminar cortex, (iv) comparable localizations in deep
cortex/subcortical region in reported cases, (v) retained expression
of immature, developmentally regulated proteins as SOX2, TBR1,
OTX1, KCC1 and GFAPo, (vi) absence of any of the known
genetic abnormalities of LEATs following NGS, including BRAF
V600E, MYB and FGFR1 mutations (15, 25, 42, 44, 47, 50) and
(vii) NGS in the present study showing recurring synonymous
SNPs in SMO and DEPDC5 in common with cortical dysplasia
(FCD IIB) and NPRL3 SNPs noted frequently in MNVT and FCD
but not other glioneuronal tumors. Copy number variations in SMO
a receptor in the Shh pathway have been recently shown in hypo-
thalamic hamartoma associated with gelastic seizures (22) and
DEPDC5 and NPRL3 mutations reported in FCDII (5, 56). Further
Figure 3. Neuronal and glial marker expression in vacuolated cells
(VC). A. NeuN staining showed labelling of normal interstitial neurons
in the white matter, but the vacuolated cells (VC) were typically weak
or more often negative (arrowheads). Labelling of VC with (B)
neurofilament, (C) MAP2, (D) synaptophysin is shown. E. Overall,
reduced labelling with synaptophysin was observed in the cortical
nodules. F. TBR1 neuronal lineage marker shows nuclear labelling of t
VC and strong cytoplasmic labelling noted with (G) OTX and (H)
MAP1b. I. GFAPd highlighted small glial cells primarily in the nodules
at low power; inset (top) multipolar GFAPd cells in proximity to VC),
inset (bottom) GFAP conventional isoform shows opposite pattern
with more extensive labelling of the gliosis around the lesions. J.
Nuclear labelling of VC with OLIG2 whereas (K) PDGFRbeta
highlighted small multipolar cells in the nodules but not the VC. L.
SMI94 for myelin basic protein, as well as demonstrating the
diminished myelination in the white matter nodules (see also Figure
2), also showed membranous labelling of the VC (arrow).Bar580
microns (A, C, D, F–H, J)540 microns (I) and 140 microns (B, K) and
200 microns (E and I) (approximate, based on original magnifications).
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histological features in common between MVNT and FCD IIB
include the striking hypomyelination of involved white matter
which may relate to deﬁciencies in oligodendroglial lineages (46,
51, 55, 70). Also the distinctive MCM2 positivity of VC is reminis-
cent of balloon cells in FCD (61). MCM2 labelling of balloon cells
is considered not to reﬂect neoplastic cell proliferation, but cell
cycle arrest in a pathological progenitor cell type (60, 69).
Lineage and maturity of vacuolating cells
Previous reports have emphasized the preferential expression of
immature markers, including HuC/HuD, compared to mature neu-
ronal markers as NeuN in the lesional cells (7, 17, 28, 39, 68). Our
study supported evidence for mature neuronal differentiation of VC
with labelling for some anti-neuroﬁlament antibodies (particularly
SMI32) although NeuN was typically weak or negative. Expression
of DCX, a microtubule-associated protein (MAP) expressed in
migrating neuronal precursors was previously reported in a MVNT
(39) but not consistently expressed in our series. We noted however
more robust expression with MAP1b, which is highly developmen-
tally regulated but normally retained in neurogenic areas in the
adult brain or regions undergoing structural plasticity (66). Strong
expression of nodules for alpha-internexin, an intermediate neuroﬁ-
lament expressed in neuroblasts has also been previously shown in
MVNT (39, 68), but more variable expression of nestin (39, 68) in
line with our observations. We also noted intense expression of
stem cell markers SOX2 and CD34, which has been consistently
reported in CNS tumors, LEATS and FCD (35, 41, 57).
Immunohistochemistry for OTX1 showed striking labelling of
VC, highlighting the subcortical extent of the MVNT. In murine cor-
tex, homeobox gene OTX1 is expressed in mid to late gestation dur-
ing development primarily in early migrating neurones destined for
deeper cortical layers V and VI (8) particularly in the temporal lobe
(3). OTX1 null mice show temporal cortical thinning (12) and sponta-
neous seizures (3). In the developing human brain, OTX1 is strongly
expressed in the forebrain and proliferative layers of the neocortical
precursors (30) as we also observed. In mature human cortex, OTX1
has been shown to be expressed in layer V pyramidal neurones (29,
38) as well as immature cells in FCD I and II (20, 29). The consistent
expression of OTX1 in MVNT, appeared more pronounced than
observed in ganglioglioma or the dysmorphic neurones of FCD (20)
and could suggest that VC are derived from incomplete maturation or
migration of progenitors destined for the deeper cortical layers. This
could be one explanation for the predominant location of MVNT in
deeper cortex compared to outer cortical layers. Focal TBR1 expres-
sion in VC is further support for their derivation from radial migrating
progenitor cells or possibly subplate remnants (16).
Glial differentiation and myelination
GFAP in MVNT highlighted a variable reactive glial component
merging with an adjacent gliotic parenchyma, in keeping with previ-
ous observations (7, 24). However, using isoform GFAPd we
observed distinct populations of intra-lesional cells as evidence for a
glial-cell component associated with MVNT. GFAPd is normally
restricted to glia residing in stem cell niches including the subventric-
ular zone (65) as well as some malformations (29, 36) and astrocytic
tumors (11) but with a less consistent expression in reactive gliosis
(27). Furthermore, preferential labelling of smaller intralesional cells,
rather than the VC, for pS6, PDGFRb, PAX6 and nestin also argues
for a mixed cellular composition in MVNT. Uniform labelling of
both the VC and the smaller cells in MVNT for OLIG2 has been pre-
viously reported (7, 17, 24, 39, 68) and conﬁrmed in our series. This
transcription factor has a recognized oncogenic role in glioma growth
(64), however in MVNT OLIG2 expression is noted in the context
of overall reduced myelination and labelling of VC for myelin basic
protein. One further hypothesis is that VC originate from OLIG2-
positive oligodendroglial progenitor cell types (OPC) (23) with
developmentally arrested or partial maturation, resulting in defective
myelination (9) and even aberrant neuronal differentiation (19).
Indeed an occasionally observation in MVNT in this and previous
reports (24) has been clustering of VC along vessels, reminiscent of
developmental migration patterns of OPC (63). Recent description of
a novel subtype of mild malformation of cortical development in
frontal lobe epilepsy, associated with increased OLIG2 cells in the
deep cortical layers and superﬁcial white matter with myelin loss
also draws comparison with MVNT (52).
Neuroimaging, clinical presentation
Characteristic appearances reported in MRI of MVNT include
multi-nodularity (7, 68), satellite nodules away from a main lesion
(Nagaishi, Yokoo, et al., 2015), hyperintensity on T2 and FLAIR
and preferential involvement of the grey-white matter junction fol-
lowing gyral contours, sometimes with a corrugated outer margin
(Fukushima, Yoshida, et al., 2015). Combinations of these imaging
features may enable the future distinction of MVNT pre-
Figure 4. Immature and interneuronal markers in multinodular and
vacuolating neuronal tumour. A. PAX6 was negative in vacuolated
cells (VC) but labelled nuclei of small cells within the lesion. B. SOX2
showed strong labelling of the nodules and VC highlighting the
regions of involvement at low magnification (C) CD34 showed
variation in the staining between cases, but as shown here in Case 5,
prominent multipolar cells and processes were evident in the regions
with VC. D. Occasional doublecortin positive (DCX) VC were seen. E.
VC were mainly nestin negative but occasional positive cells were
seen (inset left). Small nestin expressing cells were noted in the
lesion and occasional bipolar cell (inset right). F. NPY showed reduced
labelling in nodules of one MVNT (Case 4), arrows showing the edge
of the nodule; NPY staining labelled scattered interneurons in the
lesion of normal morphology but the VC were negative (arrowed in
inset). G. Case 3 showing strong labelling of VC for parvalbumin. H.
Cationic chloride transporter ((N/KCC1) with distinct cytoplasmic
labelling of the VC. I. AT8 labelling for phosphorylated tau in Case 4
with Alzheimer’s disease pathology, and dense cortical tau in tangles
and threads showed a marked sparing of the VC and nodules on
MVNT for tau accumulation (arrows). J. VC were strongly positive
with p62 and (K) anti-mitochondrial antibodies. L. VC were not posi-
tive with both pS6 markers pS6 Ser240/244 (shown here) and pS6
Ser 235/236, apart from occasional dot-like positivity in the cytoplasm
of uncertain significance (insert left); in contrast the overlying cortex
(insert left) showed strong scattered neuronal positivity. M. A high
proportion of VC were MCM2 nuclear positive. Bar550 microns (A,
D, E, G, H, K–M)5 20 microns (B, F, I, J) (approximate based on origi-
nal magnifications).
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operatively from other LEATs, gliomas and FCD. Interval MRI
has also shown a lack of growth over 18 months (7, 24) as also sup-
ported by longer pre-operative observational periods in this series.
From the 24 cases of MVNT reported (7, 17, 24, 68), the mean
age at the time of surgery is 44.6 years. Although epilepsy was
present in all our surgical samples it has been documented in just
less than half of reported cases with an average age of onset of seiz-
ures of around 30 years. However, we include the youngest case,
operated at 6 years conﬁrming MVNT may be encountered in the
pediatric age-group. MVNT predominate in the temporal lobe with
18 of the 24 reported cases arising here, with a mesial component
in eleven (7, 17, 24, 39, 68). ‘Ribbon-like’ extensions of the tumour
along the hippocampal formation and subiculum have been previ-
ously described, (68) and was striking in ﬁve of our cases which
could potentially enhance hippocampal epileptogenicity, although
presence of associated hippocampal sclerosis is variable.
Epileptogensis and neurodegeneration
An older age at manifestation of epilepsy in MVNT compared to
other epileptogenic lesions could be explained by their predominant
subcortical location with limited cortical connectivity or relative
functional inactivity. We explored acquisition of neurodegenerative
changes in the VC for several reasons: accumulation of hyperphos-
phorylated tau/neuroﬁbrillary tangle formation and p62 accumula-
tion occurs early in dysmorphic neurones of FCD and
ganglioglioma (26, 43, 54), indicating an enhanced vulnerability to
degeneration. This could be an effect of mTOR over-activity (43),
that we demonstrated in MNVT with pS6 labelling, or increased
neuronal excitability (67). By contrast in MVNT, although p62 was
prominent, there was a striking absence of tangles or phosphoryl-
ated tau with AT8 immunohistochemistry. Indeed, even in the old-
est post-mortem case with high Braak stage AD, sparing of VC and
nodules from tau accumulation was noted. Possible explanations
include a functional disconnection of MVNT from the adjacent cor-
tex preventing tau seeding (31) or indirectly it could reﬂect reduced
excitability of VC if tau phosphorylation is activity driven.
We explored other potential pro-epileptogenic cellular alterations
in MVNT as previously investigated in related pathologies (2, 53,
58, 59) (Supporting Information Table S3). We identiﬁed some evi-
dence for cation-chloride cotransporter (KCC1/KCC2) imbalances
in VC in keeping with cell immaturity (37, 49), reductions of inhib-
itory interneurons within lesions, immature astroglia (48), focal
inﬂammation (14) as pro-epileptogenic cellular alterations, that
could operate in MVNT but warrant further in-depth investigation.
In conclusion, MVNT are uncommon but distinct lesions mainly
presenting in the temporal lobe in older patients with seizures.
They appear indolent and lack any of the common mutations identi-
ﬁed in LEATS or morphologically similar malformations. Our
studies support a mixed cellular composition and expression of a
range of immature markers which could indicate an origin from an
aberrant progenitor cell type during development.
Note added in proof
Since submission of this study, further cases and series have been
reported, attesting to the indolent nature of MNVT (1, 4, 10, 40).
ACKNOWLEDGMENTS
This work is supported by the Medical Research Council (grant MR/
JO127OX/1). This work was undertaken at UCLH/UCL who
received a proportion of funding from the Department of Health’s
NIHR Biomedical Research Centres funding scheme. The Epilepsy
Society Brain and Tissue Bank at UCL is funded by the Epilepsy
Society. EA is supported by the AMC Foundation, KIKA (Stichting
Kinderen Kankervrij; AB) and Stichting Knip. We are grateful to
Avanita Prabowo for skillful technical assistance. We conﬁrm that
we have read the Journal’s position on issues involved in ethical pub-
lication and afﬁrm that this report is consistent with those guidelines.
REFERENCES
1. Alsufayan R, Alcaide-Leon P, de Tilly LN, Mandell DM, Krings T
(2017) Natural history of lesions with the MR imaging appearance of
multinodular and vacuolating neuronal tumor. Neuroradiology. doi:
10.1007/s00234-017-1884-1. [Epub ahead of print].
2. Aronica E, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D,
Gorter JA (2007) Differential expression patterns of chloride
transporters, Na1-K1-2Cl – cotransporter and K1-Cl – cotransporter,
in epilepsy-associated malformations of cortical development.
Neuroscience 145:185–196.
3. Avanzini G, Spreaﬁco R, Cipelletti B, Sancini G, Frassoni C,
Franceschetti S et al (2000) Synaptic properties of neocortical neurons
in epileptic mice lacking the Otx1 gene. Epilepsia 41:S200–S205.
4. Badat N, Savatovsky J, Charbonneau F, Collin A, Lecler A (2017)
Multinodular vacuolating and neuronal tumor of the cerebrum.
Neurology 89:304–305.
5. Baulac S, Ishida S, Marsan E, Miquel C, Biraben A, Nguyen DK et al
(2015) Familial focal epilepsy with focal cortical dysplasia due to
DEPDC5 mutations. Ann Neurol 77:675–683.
6. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini
A et al (2011) The clinicopathologic spectrum of focal cortical
dysplasias: a consensus classiﬁcation proposed by an ad hoc Task Force
of the ILAE Diagnostic Methods Commission. Epilepsia 52:158–174.
7. Bodi I, Curran O, Selway R, Elwes R, Burrone J, Laxton R et al
(2014) Two cases of multinodular and vacuolating neuronal tumour.
Acta Neuropathol Commun 2:7. doi:10.1186/2051-5960-2-7.
8. Boyl PP, Signore M, Annino A, Barbera JP, Acampora D, Simeone A
(2001) Otx genes in the development and evolution of the vertebrate
brain. Int J Dev Neurosci 19:353–363.
9. Bradl M, Lassmann H (2010) Oligodendrocytes: biology and
pathology. Acta Neuropathol 119:37–53.
10. Cathcart SJ, Klug JR, Helvey JT, L White M, Gard AP, McComb RD
(2017) Multinodular and vacuolating neuronal tumor: a rare seizure-
associated entity. Am J Surg Pathol 41:1005–1010.
11. Choi KC, Kwak SE, Kim JE, Sheen SH, Kang TC (2009) Enhanced
glial ﬁbrillary acidic protein-delta expression in human astrocytic
tumor. Neurosci Lett 463:182–187.
12. Cipelletti B, Avanzini G, Vitellaro-Zuccarello L, Franceschetti S,
Sancini G, Lavazza T et al (2002) Morphological organization of
somatosensory cortex in Otx1(2/2) mice. Neuroscience 115:657–667.
13. Crino PB (2016) The mTOR signalling cascade: paving new roads to
cure neurological disease. Nat Rev Neurol 12:379–392.
14. de Vries EE, van den Munckhof B, Braun KP, van Royen-Kerkhof A,
de Jager W, Jansen FE (2016) Inﬂammatory mediators in human
epilepsy: a systematic review and meta-analysis. Neurosci Biobehav
Rev 63:177–190.
15. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ
et al (2010) Activating mutations in BRAF characterize a spectrum of
pediatric low-grade gliomas. Neuro-oncology 12:621–630.
MNVT: Dysplasia or Neoplasia Thom et al
168 Brain Pathology 28 (2018) 155–171
VC 2017 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
16. Englund C, Fink A, Lau C, Pham D, Daza RA, Bulfone A et al (2005)
Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia,
intermediate progenitor cells, and postmitotic neurons in developing
neocortex. J Neurosci 25:247–251.
17. Fukushima S, Yoshida A, Narita Y, Arita H, Ohno M, Miyakita Y et al
(2015) Multinodular and vacuolating neuronal tumor of the cerebrum.
Brain Tumor Pathol 32:131–136.
18. Garbelli R, de Bock F, Medici V, Rousset MC, Villani F, Boussadia B
et al (2015) PDGFRbeta(1) cells in human and experimental neuro-
vascular dysplasia and seizures. Neuroscience 306:18–27.
19. Guo F, Maeda Y, Ma J, Xu J, Horiuchi M, Miers L et al (2010)
Pyramidal neurons are generated from oligodendroglial progenitor cells
in adult piriform cortex. J Neurosci 30:12036–12049.
20. Hadjivassiliou G, Martinian L, Squier W, Blumcke I, Aronica E,
Sisodiya SM, ThomM (2010) The application of cortical layer markers
in the evaluation of cortical dysplasias in epilepsy. Acta Neuropathol
120:517–528.
21. Hevner RF (2015) Brain overgrowth in disorders of RTK-PI3K-AKT
signaling: a mosaic of malformations. Semin Perinatol 39:36–43.
22. Hildebrand MS, Grifﬁn NG, Damiano JA, Cops EJ, Burgess R, Ozturk
E et al (2016) Mutations of the sonic hedgehog pathway underlie
hypothalamic hamartoma with gelastic epilepsy. Am J Hum Genet 99:
423–429.
23. Huang H, Zhao XF, Zheng K, Qiu M (2013) Regulation of the timing
of oligodendrocyte differentiation: mechanisms and perspectives.
Neurosci Bull 29:155–164.
24. Huse JT, Edgar M, Halliday J, Mikolaenko I, Lavi E, RosenblumMK
(2013) Multinodular and vacuolating neuronal tumors of the cerebrum: 10
cases of a distinctive seizure-associated lesion. Brain Pathol 23:515–524.
25. Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E
et al (2017) Polymorphous low-grade neuroepithelial tumor of the
young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-
like components, aberrant CD34 expression, and genetic alterations
involving the MAP kinase pathway. Acta Neuropathol 133:417–429.
26. Iyer A, Prabowo A, Anink J, Spliet WG, van Rijen PC, Aronica E
(2014) Cell injury and premature neurodegeneration in focal
malformations of cortical development. Brain Pathol 24:1–17.
27. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen
AH et al (2012) GFAP isoforms in adult mouse brain with a focus on
neurogenic astrocytes and reactive astrogliosis in mouse models of
Alzheimer disease. PLoS One 7:e42823.
28. Komori T, Arai N (2013) Dysembryoplastic neuroepithelial tumor, a
pure glial tumor? Immunohistochemical and morphometric studies.
Neuropathology 33:459–468.
29. Lamparello P, Baybis M, Pollard J, Hol EM, Eisenstat DD, Aronica E,
Crino PB (2007) Developmental lineage of cell types in cortical
dysplasia with balloon cells. Brain 130:2267–2276.
30. Larsen KB, Lutterodt MC, Mollgard K, Moller M (2010) Expression
of the homeobox genes OTX2 and OTX1 in the early developing
human brain. J Histochem Cytochem 58:669–678.
31. Lewis J, Dickson DW (2016) Propagation of tau pathology:
hypotheses, discoveries, and yet unresolved questions from
experimental and human brain studies. Acta Neuropathol 131:27–48.
32. Liu JY, Ellis M, Brooke-Ball H, de Tisi J, Eriksson SH, Brandner S
et al (2014) High-throughput, automated quantiﬁcation of white matter
neurons in mild malformation of cortical development in epilepsy. Acta
Neuropathol Commun. 2:72. doi:10.1186/2051-5960-2-72.
33. Louis DN, Ohgaki H, Wiestler OD Cavenee WKe WHO Classiﬁcation
of Tumours of the Central Nervous System, revised 4th edn. Edition
ISBN 978-92-832-4492-9.
34. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-
Branger D, Cavenee WK et al (2016) The 2016 World Health
Organization Classiﬁcation of Tumors of the Central Nervous System:
a summary. Acta Neuropathol 131:803–820.
35. Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD,
Zadeh G (2016) Sox2: regulation of expression and contribution to
brain tumors. CNS Oncol 5:159–173.
36. Martinian L, Boer K, Middeldorp J, Hol EM, Sisodiya SM, Squier
W et al (2009) Expression patterns of glial ﬁbrillary acidic protein
(GFAP)-delta in epilepsy-associated lesional pathologies.
Neuropathol Appl Neurobiol 35:394–405.
37. Medina I, Friedel P, Rivera C, Kahle KT, Kourdougli N, Uvarov P,
Pellegrino C (2014) Current view on the functional regulation of the
neuronal K(1)-Cl(2) cotransporter KCC2. Front Cell Neurosci 8:27.
doi:10.3389/fncel.2014.00027. eCollection 2014. Review.
38. Molnar Z, Cheung AF (2006) Towards the classiﬁcation of
subpopulations of layer V pyramidal projection neurons. Neurosci Res
55:105–115.
39. Nagaishi M, Yokoo H, Nobusawa S, Fujii Y, Sugiura Y, Suzuki R
et al (2015) Localized overexpression of alpha-internexin within
nodules in multinodular and vacuolating neuronal tumors.
Neuropathology 35:561–568.
40. Nunes RH, Hsu CC, da Rocha AJ, do Amaral LLF, Godoy LFS,
Watkins TW et al (2017) Multinodular and vacuolating neuronal tumor
of the cerebrum: a new “Leave Me Alone” lesion with a characteristic
imaging pattern. Am J Neuroradiol. doi:10.3174/ajnr.A5281. [Epub
ahead of print].
41. Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, ThomM et al
(2010) Early progenitor cell marker expression distinguishes type II
from type I focal cortical dysplasias. J Neuropathol Exp Neurol 69:
850–863.
42. Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van
Meeteren AY, Spliet WG et al (2014) BRAF V600E mutation is
associated with mTOR signaling activation in glioneuronal tumors.
Brain Pathol 24:52–66.
43. Prabowo AS, Iyer AM, Veersema TJ, Anink JJ, Schouten-van
Meeteren AY, Spliet WG et al (2015) Expression of neurodegenerative
disease-related proteins and caspase-3 in glioneuronal tumours.
Neuropathol Appl Neurobiol 41:e1–e15.
44. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD
et al (2016) Genetic alterations in uncommon low-grade
neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur
at high frequency and align with morphology. Acta Neuropathol
131:833–845.
45. Ratilal B, McEvoy A, Sisodiya S, Thom M, Toma A (2007) Diffuse
cerebral gangliocytoma in an adult with late-onset refractory epilepsy.
Neuropathol Appl Neurobiol 33:706–709.
46. Reeves C, Tachrount M, Thomas D, Michalak Z, Liu J, Ellis M et al
(2016) Combined ex vivo 9.4T MRI and quantitative histopathological
study in normal and pathological neocortical resections in focal
epilepsy. Brain Pathol 26:319–333.
47. Rivera B, Gayden T, Carrot-Zhang J, Nadaf J, Boshari T, Faury D
et al (2016) Germline and somatic FGFR1 abnormalities in
dysembryoplastic neuroepithelial tumors. Acta Neuropathol 131:
847–863.
48. Robel S, Sontheimer H (2016) Glia as drivers of abnormal neuronal
activity. Nat Neurosci 19:28–33.
49. Ruffolo G, Iyer A, Cifelli P, Roseti C, Muhlebner A, van Scheppingen
J et al (2016) Functional aspects of early brain development are
preserved in tuberous sclerosis complex (TSC) epileptogenic lesions.
Neurobiol Dis 95:93–101.
50. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-
Mende C et al (2011) Analysis of BRAF V600E mutation in 1,320
nervous system tumors reveals high mutation frequencies in
pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar
pilocytic astrocytoma. Acta Neuropathol 121:397–405.
51. Scholl T, Muhlebner A, Ricken G, Gruber V, Fabing A, Samueli S
et al (2016) Impaired oligodendroglial turnover is associated with
Thom et al MNVT: Dysplasia or Neoplasia
Brain Pathology 28 (2018) 155–171
VC 2017 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
169
myelin pathology in focal cortical dysplasia and tuberous sclerosis
complex. Brain Pathol. doi:10.1111/bpa.12452. [Epub ahead of print].
52. Schurr J, Coras R, Rossler K, Pieper T, Kudernatsch M, Holthausen H
et al (2016) Mild malformation of cortical development with
oligodendroglial hyperplasia in frontal lobe epilepsy: a new clinico-
pathological entity. Brain Pathol 27:26–35.
53. Sen A, Martinian L, Nikolic M, Walker MC, Thom M, Sisodiya SM
(2007) Increased NKCC1 expression in refractory human epilepsy.
Epilepsy Res 74:220–227.
54. Sen A, ThomM, Martinian L, Harding B, Cross JH, Nikolic M,
Sisodiya SM (2007) Pathological tau tangles localize to focal cortical
dysplasia in older patients. Epilepsia 48:1447–1454.
55. Shepherd C, Liu J, Goc J, Martinian L, Jacques TS, Sisodiya SM,
Thom M (2013) A quantitative study of white matter hypomyelination
and oligodendroglial maturation in focal cortical dysplasia type II.
Epilepsia 54:898–908.
56. Sim JC, Scerri T, Fanjul-Fernandez M, Riseley JR, Gillies G, Pope K
et al (2016) Familial cortical dysplasia caused by mutation in the
mammalian target of rapamycin regulator NPRL3. Ann Neurol 79:
132–137.
57. Thom M, Blumcke I, Aronica E (2012) Long-term epilepsy-associated
tumors. Brain Pathol 22:350–379.
58. Thom M, Harding BN, Lin WR, Martinian L, Cross H, Sisodiya SM
(2003) Cajal–Retzius cells, inhibitory interneuronal populations and
neuropeptide Y expression in focal cortical dysplasia and
microdysgenesis. Acta Neuropathol 105:561–569.
59. Thom M, Martinian L, Parnavelas JG, Sisodiya SM (2004)
Distribution of cortical interneurons in grey matter heterotopia in
patients with epilepsy. Epilepsia 45:916–923.
60. Thom M, Martinian L, Sen A, Squier W, Harding BN, Cross JH et al
(2007) An investigation of the expression of G1-phase cell cycle
proteins in focal cortical dysplasia type IIB. J Neuropathol Exp Neurol
66:1045–1055.
61. Thom M, Martinian L, Sisodiya SM, Cross JH, Williams G, Stoeber K
et al (2005) Mcm2 labelling of balloon cells in focal cortical dysplasia.
Neuropathol Appl Neurobiol 31:580–588.
62. Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B et al
(2011) One hundred and one dysembryoplastic neuroepithelial tumors:
an adult epilepsy series with immunohistochemical, molecular genetic,
and clinical correlations and a review of the literature. J Neuropathol
Exp Neurol 70:859–878.
63. Tsai HH, Niu J, Munji R, Davalos D, Chang J, Zhang H et al (2016)
Oligodendrocyte precursors migrate along vasculature in the
developing nervous system. Science 351:379–384.
64. Tsigelny IF, Kouznetsova VL, Lian N, Kesari S (2016) Molecular
mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget
7:53074–53101.
65. van den Berge SA, Middeldorp J, Zhang CE, Curtis MA, Leonard
BW, Mastroeni D et al (2010) Longterm quiescent cells in the aged
human subventricular neurogenic system speciﬁcally express GFAP-
delta. Aging Cell 9:313–326.
66. Villarroel-Campos D, Gonzalez-Billault C (2014) The MAP1B case:
an old MAP that is new again. Dev Neurobiol 74:953–971.
67. Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K
et al (2016) Neuronal activity enhances tau propagation and tau
pathology in vivo. Nat Neurosci 19:1085–1092.
68. Yamaguchi M, Komori T, Nakata Y, Yagishita A, Morino M,
Isozaki E (2016) Multinodular and vacuolating neuronal tumor
affecting amygdala and hippocampus: a quasi-tumor? Pathol Int
66:34–41.
69. Yasin SA, Latak K, Becherini F, Ganapathi A, Miller K, Campos O
et al (2010) Balloon cells in human cortical dysplasia and tuberous
sclerosis: isolation of a pathological progenitor-like cell. Acta
Neuropathol 120:85–96.
70. Zucca I, Milesi G, Medici V, Tassi L, Didato G, Cardinale F et al
(2016) Type II focal cortical dysplasia: ex vivo 7T magnetic resonance
imaging abnormalities and histopathological comparisons. Ann Neurol
79:42–58.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1. Comparative Labelling In Ganglioglioma Cases,
TLE/Temporal Lobe In Temporal Lobe Epilepsy With Increased
White Matter Neurones (Equivalent To Mild MCD/Malforma-
tion Of Cortical Development Type II) And Developmental
Controls Of 13 Gestational Weeks. A. Tbr1 in gangliogliomas
showed strong nuclear labelling in two cases as shown, but neg-
ative labelling in two further cases (not shown). B. OTX1 in
ganglioglioma showed cytoplasmic positivity of dysmorphic
neurons in a proportion of cases. C. SOX2 in gangliogliomas
showed granular cytoplasmic (or peripheral cytoplasmic stain-
ing) of dysplastic ganglion cells which was variable between
cases. D. OLIG2 was negative in the atypical neuronal cells of
gangliogliomas or showed cytoplasmic granular staining but
nuclear labelling was not a feature; (inset) PDGFRb did not
label the atypical ganglion cells. E. Calbindin showed strong
labelling of the tumour and parenchyma with a sharp border
with adjacent tissue and intense labelling of dysmorphic neuro-
nal cells (inset). F. MCM2 labelling in gangliogliomas high-
lighted inﬂammatory cell component with variable nuclear
positivity in a small proportion of the ganglion cells. G. TBR1
showed labelling of white matter neurons in mild MCD. H.
There was no labelling of OTX1 in the white matter neurons
with OTX1 in mild MCD and weak cytoplasmic labelling of
small glial cells. I. In mild MCD, occasional weak cytoplasmic
labelling of the single white matter neurons for SOX2 was
noted. J. In mild MCD, the neuronal cells were not OLIG2 pos-
itive and only labelling of the small oligodendroglial cells seen.
K. phosphor-S6 labelling in mild MCD showed occasional
labelling of the single white matter neurons and small glial cells
and (L) KCC1 did not label the white matter neurons in Mild
MCD. M. TBR2 in fetal cortex showed labelling of immature
cells in the germinal matrix and in the periventricular zone and
developing white matter. N. OTX1 in developmental controls
showed a strong, predominantly peripheral ring of cytoplasmic
labelling of the germinal matrix cells. O. With SOX2 strong
labelling of primitive cells in the germinal matrix was seen.
Bar5 50 microns (A–D,F,H–O); 5100 microns in E and 200
microns on G (approximate based on original magniﬁcations).
Table S1. Detail of the control cases used for comparative
staining with the multinodular vacuolating neuronal tumour.
These were used only for the markers where there is little
available data in literature of labelling patterns. These con-
trols tissues were selected from the University College Lon-
don Epilepsy Society Brain and Tissue Bank. The staining
patterns of control cases are shown in supplemental Figure 1
and is referred to in Supporting Information Table 2. TLE5
temporal lobe epilepsy; MCD5malformation of cortical
development
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Table S2. Less frequent variants identiﬁed on NGS of eight
cases of MNVT. 11 different polymorphism were identiﬁed
involving 8 of the 33 genes tested.
Table S3. Comparison of growth patterns of multinodular
vacuolating neuronal tumour (MNVT) and immunophenotypic
characteristics of the atypical neuronal cells and vacuolated cells
compared to other common cortical epilepsy pathologies in the
main differential diagnosis: dysembryoplastic neuroepithelial
tumour (DNT; classical form), ganglioglioma, focal cortical
dysplasia (FCD IIB), mild malformation of cortical development
type II (Mild MCD) and heterotopia. This is as based in reports
in literature (as referenced in table), data reported in current
study or personal non- published observation. In Bold font
the more potentially useful markers/tests to discriminate MNVT
from other lesions in their differential diagnosis are highlighted.
The diagnostic criteria for each lesion are based on WHO 2016
for tumours and ILAE for cortical malformations (44).
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